In This Section

Program

Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract
[R] – Remote Presentation

Wednesday, June 19

Thursday, June 20

Friday, June 21

Saturday, June 22

Wednesday, June 19

REGISTRATION

3:30-8:30 p.m. | Liberty Foyer

WELCOME AND OPENING Keynote lecture

6-7 p.m. | Liberty B | CME Eligible

  • 6 p.m. | Welcome and Introduction of Keynote Speaker
    Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 6:10 p.m. | Keynote Lecture
    Metabolic regulation of lymphoma development
    Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

Plenary Session 1: Signaling/immune synapse

7-8:45 p.m. | Liberty B | CME Eligible

Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

  • 7:05 p.m. | Oncogenic signaling in T-cell and B-cell lymphoma
    Jürgen Ruland, Technical University of Munich, Munich, Germany
    7:25 p.m. | Q&A
  • 7:30 p.m. | Lymphoma immune microenvironment shaping receptivity to various immunological therapeutic strategies
    Roberta Zappasodi, Weill Cornell Medicine, New York, New York
    7:50 p.m. | Q&A
  • 7:55 p.m. | BTK inhibitor resistance
    Francesco Bertoni
    8:15 p.m. | Q&A
  • 8:20 p.m. | Panel Discussion/Q&A

OPENING RECEPTION

8:45-10:15 p.m. | Liberty A

Thursday, June 20

CONTINENTAL BREAKFAST

7:30-8:30 a.m. | Liberty A

spotlight on proffered papers session

8:30-9:55 p.m. | Liberty B | CME Eligible

Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 8:35 a.m. | EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions*
    Yusuke Isshiki, Weill Cornell Medicine, New York, New York
  • 8:46 a.m. | Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients*
    Nahuel Zamponi, Weill Cornell Medicine, New York, New York
  • 8:57 a.m. | Immunosurveillance of precancerous germinal center B cells*
    Dinis Pedro Parente Calado, The Francis Crick Institute, London, United Kingdom
  • 9:08 a.m. | Characterization of an essential MYC enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma*
    Aishwarya Gurumurthy, University of Michigan, Ann Arbor, Michigan
  • 9:19 a.m. | Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas*
    Wen-Hsuan Wendy Lin, Columbia University Irving Medical Center, New York, New York
  • 9:19 a.m. | Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy*
    Xubin Li, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:30 a.m. | SETD1B mutations confer apoptosis resistance and BCL2 independence in B-cell Lymphoma*
    Ana Portelinha, Memorial Sloan Kettering Cancer Center, New York, New York

break

9:55-10:15 a.m. | Liberty Foyer

PLENARY SESSION 2: Germinal Center Biology and its Role in Lymphomagenesis

10:15 a.m.-12 p.m. | Liberty B | CME Eligible

Session Chair: Coraline Mlynarczyk, Weill Cornell Medicine, New York, New York

  • 10:20 a.m. | Regulating programmed DNA lesions in B cells
    Jayanta Chaudhuri, Memorial Sloan Kettering Cancer Center, New York, New York
    10:40 a.m. | Q&A
  • 10:45 a.m. | Competition in the germinal center
    Coraline Mlynarczyk
    11:05 a.m. | Q&A
  • 11:10 a.m. | T-cell dependent acquisition of stem-like plasticity in Germinal Center B cells
    Effie Apostolou, Weill Cornell Medicine, New York, New York
    11:30 a.m. | Q&A
  • 11:35 a.m. | Panel Discussion/Q&A

Free time/lunch on own

12-1:30 p.m.

Plenary Session 3: Premalignant Processes in Lymphomagenesis

1:30-3:15 p.m. | Liberty B | CME Eligible

Session Chair: Jagan Muppidi, National Cancer Institute, Bethesda, Maryland

  • 1:30 p.m. | Lymphoid clonal hematopoiesis
    Aswin Sekar, Dana-Farber Cancer Institute, Boston, Massachusetts
    1:55 p.m. | Q&A
  • 2 p.m. | Spontaneous germinal centers and lymphoma hallmark lesions
    Jagan Muppidi
    2:20 p.m. | Q&A
  • 2:25 p.m. | Expanded clones of T cells with lymphoma driver mutations in unexplained cases of refractory celiac disease
    Mandeep Singh, Garvin Institute of Medical Research, Sydney, Australia
    2:45 p.m. | Q&A
  • 2:50 p.m. | Panel Discussion/Q&A

Break

3:15-3:35 p.m. | Liberty Foyer

Plenary Session 4: Lymphoma Clonal Precursors and Transformation

3:35-5:20 p.m. | Liberty B | CME Eligible

Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, New York

  • 3:40 p.m. | The elusive lymphoma clonal precursor cell
    Ari M. Melnick
    4 p.m. | Q&A
  • 4:05 p.m. | Deciphering and intercepting follicular lymphoma clonal precursor cells
    Sandrine Roulland, Aix-Marseille University, Marseille, France
    4:25 p.m. | Q&A
  • 4:30 p.m. | Transformation to aggressive lymphoma: Molecular basis and detection
    Erin M. Parry, Dana-Farber Cancer Institute, Boston, Massachusetts
    4:50 p.m. | Q&A
  • 4:55 p.m. | Panel Discussion/Q&A

Poster session/reception

5:30-7:30 p.m. | Liberty A

Friday, June 21

CONTINENTAL BREAKFAST

7:30-8:30 a.m. | Liberty A

Plenary Session 5: Lymphoma Etiology and Outcomes: The Role of Age and Ethnicity

8:30-10:15 a.m. | Liberty B | CME Eligible

Session Chair: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 8:30 a.m. | The etiology of pediatric lymphoma
    Lisa G. Roth, Weill Cornell Medicine, New York, New York
    8:55 a.m. | Q&A
  • 9 a.m. | An aged/autoimmune origin to B cell lymphomas
    Leandro Venturutti, BC Cancer, Vancouver, BC, Canada
    9:20 a.m. | Q&A
  • 9:25 a.m. | Disparities in lymphoma
    Christopher R. Flowers
    9:45 a.m. | Q&A
  • 9:50 a.m. | Panel Discussion/Q&A

break

10:15-10:35 a.m. | Liberty Foyer

Plenary Session 6: Lymphoma Epigenetics

10:35 a.m.-12:15 p.m. | Liberty B | CME Eligible

Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 10:40 a.m. | Epigenetic therapies in T-cell lymphoma
    Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, New York
    11 a.m. | Q&A
  • 11 a.m. | Disentangling truncating and missense CREBBP mutations in B cell lymphoma
    Laura Pasqualucci, Columbia University, Institute for Cancer Genetics, New York, New York
    11:20 a.m. | Q&A
  • 11:25 a.m. | Perturbation of cell state transitions by epigenetic mutations
    Michael R. Green
    11:45 a.m. | Q&A
  • 11:50 a.m. | Panel Discussion/Q&A

Free time/lunch on own

12:15-1:45 p.m.

Plenary Session 7: Lymphoma Microenvironment / Tumor Immunology of Lymphoma

1:45-3:30 p.m. | Liberty B | CME Eligible

Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, Massachusetts

  • 1:50 p.m. | Bispecific antibodies in lymphoma therapy
    Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark
    2:10 p.m. | Q&A
  • 2:15 p.m. | The lymphoma microenvironment
    Margaret A. Shipp
    2:35 p.m. | Q&A
  • 2:40 p.m. | Multi-omic profiling of the follicular lymphoma tumor microenvironment
    Andrea J. Radtke, National Institute of Allergy and Infectious Disease, Bethesda, Maryland
    3 p.m. | Q&A
  • 3:05 p.m. | Panel Discussion/Q&A

Break

3:30-3:50 p.m. | Liberty Foyer

Plenary Session 8: New Approaches in CAR T-cell Therapy

3:30-5:30 p.m. | Liberty B | CME Eligible

Session Chair: Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

  • 3:55 p.m. | Logic gating of CAR T cells: OR and IF-BETTER
    Michel Sadelain
    4:15 p.m. | Q&A
  • 4:20 p.m. | Clonotype-specific CAR T
    Marco Ruella, University of Pennsylvania, Philadelphia, PA
    4:40 p.m. | Q&A
  • 4:55 p.m. | How to make CART cells work in spite of lymphoma immune evasion mechanisms
    Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, New York
    5:05 p.m. | Q&A
  • 5:10 p.m. | Panel Discussion/Q&A

Evening off

5:30 p.m.

Saturday, June 22

CONTINENTAL BREAKFAST

7-8 a.m. | Liberty A

keynote lecture

8-9 a.m. | Liberty B | CME Eligible

  • 8:05 a.m. | Keynote Lecture
    Toward the noninvasive characterization of lymphomas & their microenvironments
    Ash A. Alizadeh, Stanford University, Stanford, California

Plenary Session 9: Chemo-free Approaches to Lymphoma

9-10:45 a.m. | Liberty B | CME Eligible

Session Chair: Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 9:05 a.m. | We will still use RCHOP in 2034?
    Jason Westin
    9:25 a.m. | Q&A
  • 9:30 a.m. | Targeted treatment of DLBCL
    Christopher Melani, National Cancer Institute, Bethesda, Maryland
    9:50 a.m. | Q&A
  • 9:55 a.m. | Rewiring cancer drivers to activate apoptosis
    Gerald R. Crabtree, Stanford University, Stanford, California
    10 a.m. | Q&A
  • 10:20 a.m. | Panel Discussion/Q&A

break

10:45-11 a.m. | Liberty Foyer

Plenary Session 10: Bringing Genomics from Bench to Bedside

11 A.M.-12:45 p.m. | Liberty B | CME Eligible

Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 11:05 a.m. | Precision therapy based on somatic mutation profiles
    H. Christian Reinhardt, Essen University Hospital, Essen, Germany
    11:25 a.m. | Q&A
  • 11:30 a.m. | T-cell lymphoma molecular classifications that inform therapy
    Catalina Amador, University of Miami Miller School of Medicine, Miami, Florida
    11:50 a.m. | Q&A
  • 11:55 a.m. | Genetic subtype-guided immunochemotherapy in DLBCL [R]
    Wei-Li Zhao, Ruijin Hospital, Shanghai, China
    12:15 p.m. | Q&A
  • 12:20 p.m. | Panel Discussion/Q&A

Departure

12:45 p.m.